Seattle Genetics Secures $9,000,000 New Financing Round

  • Feed Type
  • Date
    1/21/2014
  • Company Name
    Seattle Genetics
  • Mailing Address
    21823 30th Drive S.E Bothell, WA 98021
  • Company Description
    Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
  • Website
    http://www.seattlegenetics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $9,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Seattle Genetics and Takeda are jointly developing Adcetris, which has been approved in 39 countries.
  • M&A Terms
  • Venture Investor
    Takeda Ventures

Trending on Xconomy